Elizabeth Thoburn

Elizabeth Thoburn

Auto-generated profile, based on publicly available information

Elizabeth Thoburn

Pfizer, Inc., New York, NY, USA.

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2024 in Journal of Medical Economics
Verified
Journal Article
Open access
AYAlon Yehoshua
Alon Yehoshua
ACAngela D. Cook
Angela D. Cook
MDManuela DiFusco
Manuela DiFusco
ARAbby E. Rudolph
Abby E. Rudolph
ETElizabeth Thoburn
Elizabeth Thoburn
KAKathleen M. Andersen
Kathleen M. Andersen
Conduct a comprehensive analysis of the health and economic outcomes of patients with a COVID-19-associated hospitalization in the US during the predominance of the XBB and JN.1 Omicron lineages. This analysis used data from the PINC AI Healthcare Database (PHD) for all patients with a hospital admission date occurring between February 4, 2023, and February 29, 2024 with an ICD-10-CM code U07.1 "COVID-19" in any position. The data were used to estimate the mean and median length of stay (LOS), mean and median hospitalization cost, and proportion of patients that died in the hospital, by age and level of care (normal ward, intensive care [ICU], invasive mechanical ventilation [IMV]). LOS, hospitalization costs, and inpatient mortality increased with both the level of care and age. Patients not receiving ICU care had the shortest LOS, lowest inpatient mortality, and lowest hospitalization costs. LOS, hospitalization costs, and inpatient mortality were higher for those receiving ICU care and highest for those receiving IMV in the ICU. Within each level of care (normal ward, ICU without IMV, and ICU with IMV), the LOS, inpatient mortality, and hospitalization cost generally increased with age, indicating that older adults with COVID-19 required a longer recovery period, have a higher likelihood of death, and accrue higher costs. However, the proportion of pediatric patients with an ICU admission and/or IMV usage remained high. The PHD data may not be representative of all hospitalized patients in the US. These findings suggest that COVID-19 continues to have severe and costly consequences in all age groups, but particularly for older adults including long LOS, ICU admission, need for IMV, mortality, and high hospital costs.

7 June 2026 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
ETElizabeth Thoburn
Elizabeth Thoburn
VGVassilis G. Giannakoulis
Vassilis G. Giannakoulis
THTianyan Hu
Tianyan Hu
HGHenry Goebe
Henry Goebe
SRSheetal Raina
Sheetal Raina
SLSantiago M. C. Lopez
Santiago M. C. Lopez
Since COVID-19 vaccine introduction in December 2020, > 13 billion doses have been distributed globally, including > 5 billion Pfizer-BioNTech (BNT162b2) doses. Real-world evidence in pregnancy remains heterogenous in design and outcome definitions, with limited analysis by dose timing or variant period. Most reviews evaluated COVID-19 vaccines as a class without focus on individual products, limiting product-specific interpretation. Given expanding evidence and public concern around safety of vaccines during pregnancy, an updated, pregnancy-focused systematic review of BNT162b2 safety is warranted. This study aimed to review and synthesize evidence on the safety of Pfizer-BioNTech COVID-19 vaccine in pregnant women, including pregnancy-related outcomes. A systematic literature review (PROSPERO registered) was conducted in accordance with Cochrane methodology and reported following PRISMA guidelines. Medline and Embase were searched from December 2020 to June 2025, supplemented by regulatory reports and conference searches. Eligible randomized and observational studies reporting obstetric or neonatal outcomes after ≥ 1 dose of BNT162b2 were included. Quality appraisal was conducted using NICE checklists. Results were narratively synthesized and reported following SWiM guidance. Across 25 studies, comprising > 450,000 BNT162b2-vaccinated pregnant women, no increased risk was observed for miscarriage, congenital anomalies, preterm birth, hypertensive disorders, small for gestational age, low birth weight, or neonatal death, with effect estimates broadly consistent and centered around the null across available trimester-stratified analyses, dose numbers, and study design. However, trimester-specific data, particularly for first-trimester exposure, were limited. The cumulative evidence demonstrates a reassuring safety profile for Pfizer-BioNTech (BNT162b2) COVID-19 vaccination with no indication of increased pregnancy-related or neonatal risk. The evidence is mainly observational and heterogeneous, with limited precision for rare outcomes, but the results align with findings from international registry, surveillance, and population-based evidence and support BNT162b2 vaccination in pregnancy as an effective and safe means to reduce preventable maternal morbidity, although evidence remains limited for first-trimester-specific exposure. The review protocol was prospectively registered with PROSPERO [CRD420251080193] [1].